BIOCON

Biologics Ltd's biosimilar Yesafili (aflibercept) is now publicly funded in Ontario, Canada, for retinal diseases such as AMD, DME, and CRVO/BRVO. Yesafili is Canada's first Eylea biosimilar, and its approval is based on data from a phase 3 study, showing no clinically meaningful differences from Eylea. This funding makes treatment more accessible to over two million Canadians affected.